NYSE:BHC - Bausch Health Companies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$23.09 +0.06 (+0.26 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$23.09
Today's Range$22.74 - $23.30
52-Week Range$14.44 - $28.45
Volume3.91 million shs
Average Volume4.60 million shs
Market Capitalization$8.05 billion
P/E Ratio6.03
Dividend YieldN/A
Beta0.14
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal. The company also develops and markets products that treat gastrointestinal and hepatologic conditions comprising hepatic encephalopathy, irritable bowel syndrome with diarrhea, traveler's diarrhea, opioid-induced constipation, ulcerative colitis, and others. In addition, it offers eye health products, such as contact lens; products that treat various eye conditions, including glaucoma, eye allergies, conjunctivitis, dry eye, and retinal diseases; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for the treatment of cataracts, and vitreous and retinal eye conditions. Further, the company provides products in the therapeutic areas of epilepsy, migraines, depression, chronic pain, and rare diseases such, as huntington's disease; and oral health products for adult periodontitis and mouth dryness, as well as teeth-whitening. Additionally, it offers eye drops; skin care products, including moisturizers; and eye vitamins and mineral supplements, as well as neurology products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.

Receive BHC News and Ratings via Email

Sign-up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone514-744-6792

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.72 billion
Cash Flow$12.5489 per share
Book Value$17.05 per share

Profitability

Net Income$2.40 billion

Miscellaneous

Employees20,700
Market Cap$8.05 billion
OptionableOptionable

Bausch Health Companies (NYSE:BHC) Frequently Asked Questions

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc (NYSE:BHC) posted its quarterly earnings results on Tuesday, November, 6th. The company reported $1.15 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.84 by $0.31. The company had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.09 billion. Bausch Health Companies had a negative net margin of 40.41% and a positive return on equity of 32.19%. The company's quarterly revenue was down 3.7% on a year-over-year basis. View Bausch Health Companies' Earnings History.

When is Bausch Health Companies' next earnings date?

Bausch Health Companies is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for Bausch Health Companies.

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies updated its FY 2018 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $8.15-8.35 billion, compared to the consensus revenue estimate of $8.32 billion.

What price target have analysts set for BHC?

17 brokers have issued twelve-month target prices for Bausch Health Companies' shares. Their predictions range from $9.00 to $39.00. On average, they anticipate Bausch Health Companies' stock price to reach $26.4286 in the next twelve months. This suggests a possible upside of 14.5% from the stock's current price. View Analyst Price Targets for Bausch Health Companies.

What is the consensus analysts' recommendation for Bausch Health Companies?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 3 sell ratings, 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Bausch Health Companies.

What are Wall Street analysts saying about Bausch Health Companies stock?

Here are some recent quotes from research analysts about Bausch Health Companies stock:
  • 1. According to Zacks Investment Research, "Bausch has narrowed its focus on seven recently launched or expected to be launched products in the near future, pending completion of testing and receipt of FDA approval. After a tumultuous period, Bausch started a rebuilding process. The company recently changed its name. Even though it is still early to comment on the rebuilding process, the company’s efforts to sell non-core assets and pay down huge levels of debt are commendable. Bausch's Salix business continues to drive growth and contribute to the top line. In particular, increased sales of Xiaflex and Relistor is boosting the segment.  However, the dermatology market continues to be challenging. Shares have performed better than the industry in the last six months." (1/8/2019)
  • 2. Cantor Fitzgerald analysts commented, ". Post a beat and raise quarter, we reiterating our OW rating and 12-month price target of C$32 for BHC shares. We think a greater appreciation for BHC’s solid execution and future growth prospects should drive upwards earnings revisions as well as multiple expansion in 2019+." (11/6/2018)
  • 3. Mizuho analysts commented, "We currently model $0.5M in 2018 Bryhali sales, growing to $68.0M in 2022. Bryhali is highlighted as one of the company’s significant seven" and is expected to play a role in mgmt’s goal of doubling its dermatology business over the next 5 years. We reiterate our Buy rating and $35 PT on BHC." (10/8/2018)
  • 4. HC Wainwright analysts commented, "We note that the FDA only posed questions regarding pharmacokinetic (PK) data, and did not ask for additional information concerning safety and efficacy or chemistry, manufacturing and controls (CMC) data. In the wake of these developments, we are reiterating our Neutral rating and price target of $20 on BHC shares." (8/31/2018)

Has Bausch Health Companies been receiving favorable news coverage?

Media stories about BHC stock have been trending extremely positive on Saturday, InfoTrie reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bausch Health Companies earned a coverage optimism score of 4.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the next few days.

Who are some of Bausch Health Companies' key competitors?

Who are Bausch Health Companies' key executives?

Bausch Health Companies' management team includes the folowing people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 63)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 62)
  • Ms. Christina M. Ackermann, Exec. VP & Gen. Counsel (Age 53)
  • Mr. Thomas J. Appio, Exec. VP & Group Chairman of International (Age 56)
  • Mr. William D. Humphries, Exec. VP & Group Chairman of Dermatology (Age 52)

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Boston Advisors LLC (0.01%), Virtu Financial LLC (0.01%), Nexus Investment Management Inc. (0.01%), Iron Financial LLC (0.01%), Quadrant Capital Group LLC (0.00%) and Contravisory Investment Management Inc. (0.00%). Company insiders that own Bausch Health Companies stock include Christina Ackermann, John Paulson, Joseph C Papa, Paul Herendeen, Pershing Square Capital Manage, Schutter Richard U De, Thomas Appio and Valueact Capital Master Fund,. View Institutional Ownership Trends for Bausch Health Companies.

Which major investors are selling Bausch Health Companies stock?

BHC stock was sold by a variety of institutional investors in the last quarter, including Riggs Asset Managment Co. Inc., Iron Financial LLC and Nexus Investment Management Inc.. View Insider Buying and Selling for Bausch Health Companies.

Which major investors are buying Bausch Health Companies stock?

BHC stock was acquired by a variety of institutional investors in the last quarter, including Boston Advisors LLC, Virtu Financial LLC, Contravisory Investment Management Inc. and Quadrant Capital Group LLC. Company insiders that have bought Bausch Health Companies stock in the last two years include John Paulson, Joseph C Papa, Paul Herendeen, Schutter Richard U De, Thomas Appio and Valueact Capital Master Fund,. View Insider Buying and Selling for Bausch Health Companies.

How do I buy shares of Bausch Health Companies?

Shares of BHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $23.09.

How big of a company is Bausch Health Companies?

Bausch Health Companies has a market capitalization of $8.05 billion and generates $8.72 billion in revenue each year. The company earns $2.40 billion in net income (profit) each year or $3.83 on an earnings per share basis. Bausch Health Companies employs 20,700 workers across the globe.

What is Bausch Health Companies' official website?

The official website for Bausch Health Companies is http://www.valeant.com.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company can be reached via phone at 514-744-6792 or via email at [email protected]eant.com.


MarketBeat Community Rating for Bausch Health Companies (NYSE BHC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  272
MarketBeat's community ratings are surveys of what our community members think about Bausch Health Companies and other stocks. Vote "Outperform" if you believe BHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Featured Article: Analyst Ratings Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel